



First long-acting injectable (LAI) antipsychotic using MedinCell's technology reaches Phase 3 clinical study primary completion date

Euronext: MEDCL • Montpellier - France • Nov 12, 2020 • 5:45 pm (Paris)

The primary completion date¹ for the pivotal efficacy study to investigate mdc-IRM, an investigational subcutaneous risperidone, was reached on September 30, 2020. The estimated study completion date² has been moved forward to November 24, 2020 from January 31, 2021.

Phase 3 safety investigations continue with an estimated study completion date scheduled on December 31, 2020.

"We are pleased that mdc-IRM continues to progress through the development process," stated Christophe Douat, CEO of MedinCell. "We are excited that the first long-acting injectable antipsychotic using our proprietary technology has reached this Phase 3 clinical milestone. Our partner anticipates having the readout of the trial sometime in Q1 2021."

mdc-IRM is the most advanced in development of three antipsychotic products based on MedinCell's technology and is being developed by Teva Pharmaceuticals. There is another investigational product currently in Phase 1 (mdc-TJK), and another in preclinical development (mdc-ANG).

¹ The primary completion date is the date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. The primary outcome measure is the most important for evaluating the effect of a treatment.

² Study completion date is the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit).

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO[®] technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO[®] technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Relation investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98